Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425076 | 0.87 | GRM5 (0.39) | CYP2A6NOS3NOS2CYP11B1CYP11B2 | |
| SCHEMBL7219012 | 0.82 | CTSK (0.51) | NOS3NOS2CTSSCTSKCYP19A1 | |
| SCHEMBL3087337 | 0.80 | HCAR2 (0.38) | — | |
| SCHEMBL7219740 | 0.79 | NOS2 (0.46) | NOS2KCNH2CTSSCTSKCYP19A1 | |
| SCHEMBL9564934 | 0.76 | NOTUM (0.41) | TTRALBCYP11B1CYP11B2HSD11B1 | |
| SCHEMBL3242600 | 0.74 | CYP1A2 (0.44) | CYP2A6KCNH2CTSSCTSKCYP11B1 | |
| SCHEMBL18517735 | 0.71 | CTSK (0.47) | NOS3NOS2CTSSCTSKCYP19A1 | |
| SCHEMBL4734456 | 0.71 | NOS3 (0.35) | NOS3NOS2 | |
| SCHEMBL19539190 | 0.70 | CYP11B2 (0.44) | CYP2A6CYP11B1CYP11B2HSD11B1 | |
| SCHEMBL2607125 | 0.70 | CYP2A6 (0.58) | CYP2A6TTRALBKCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560373-B2 | Compounds and their use as PDE4 activators | MIRONID LIMITED (GB) | 2023-01-24 | — | — | US | disclosed |
| EP-3774780-B1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LTD (GB) | 2022-11-23 | — | — | EP | disclosed |
| EP-3774780-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20210032231-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2021-02-04 | — | — | US | disclosed |
| WO-2019193342-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2019-10-10 | — | — | WO | disclosed |
| US-6603007-B1 | Intermediates in the fields of pharmaceuticals, agrichemicals, ligands, silver halide photosensitive materials, liquid crystals, surfactants, electrophotography and organic electroluminescence | SANKIO CHEMICAL CO., LTD. (JP) | 2003-08-05 | — | — | US | disclosed |
| EP-1231207-A1 | NOVEL BIPYRIDYL DERIVATIVES | Sankio Chemical Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032231-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE4C | CYP2A6 1718/4885NOS3 347/4885NOS2 501/4885 |
| US-11560373-B2 | Compounds and their use as PDE4 activators | PDE4A, PDE4B, PDE4C | CYP2A6 1718/4885NOS3 347/4885NOS2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.